亞太地區急診症候群檢測市場：分析與預測（2023-2033）

2023年亞太地區急性護理綜合症檢測市場規模為7.8億美元，2023年至2033年複合年成長率為10.97%，預計2033年將達22億美元。

由於全球暖化加劇，感染疾病率增加、流行病爆發以及在各地區發現新的傳染病，因此對早期檢測感染疾病的需求不斷增加，從而推動了市場的成長。

亞太地區（亞太地區）急性護理症候群檢測市場正在經歷強勁成長，並在該地區的醫療保健形勢中佔據重要地位。症狀檢測在快速診斷和管理急性疾病以及及時應對疫情和緊急情況方面發揮著至關重要的作用。這一市場擴張是由感染疾病流行率上升、人們對早期診斷重要性的認知不斷提高以及診斷技術的進步等因素所推動的。

近年來，亞太地區在醫療保健基礎設施方面進行了大量投資，並引入了創新的診斷解決方案。這些投資加強了急性護理症候群檢測市場，使緊急護理和嚴重護理環境中的診斷更快、更準確。此外，持續的 COVID-19 大流行凸顯了症狀檢測在公共衛生應對中的關鍵作用，進一步刺激了全部區域對此類檢測解決方案的需求。

本報告探討了亞太地區急性護理綜合症檢測市場，提供了市場概述、最終用戶、國家/地區的趨勢以及參與市場的公司概況。

目錄

執行摘要

第1章 市場

• 市場範圍
• 調查方法

第2章 市場概況

• 概述
• 急性護理症候群檢測的工作流程分析
• 市場足跡和成長潛力
• 未來性

第3章業界考察

• 相關利益者觀點（N=20）
• 急診護理症候群檢測市場的法律和法律規範
• 產品基準評效

第4章市場動態

• 概述
• 影響分析
• 市場驅動力
• 市場挑戰
• 市場機會

第5章 2022-2033年急性醫學症候群檢測市場（分地區）

• 概述
• 亞太地區
  • 亞太地區急性護理症候群檢測市場，依最終用戶分類
  • 亞太地區急性護理症候群檢測市場（依國家）

第6章 公司簡介

• Acute Care Syndromic Testing Ecosystem Active Players
• Seegene Inc.
• SpeeDx

“The Asia-Pacific Acute Care Syndromic Testing Market Expected to Reach $2.20 Billion by 2033.”

Introduction to Asia-Pacific Acute Care Syndromic Testing Market

The Asia-Pacific acute care syndromic testing market was valued at $0.78 billion in 2023 and is expected to reach $2.20 billion by 2033, growing at a CAGR of 10.97% between 2023 and 2033. The growth of the market can be attributed to the rising need for early detection of infectious diseases, driven by the growing incidence of such diseases, the occurrence of pandemics, and the identification of new infectious diseases in various regions, exacerbated by global warming.

Market Introduction

The Asia-Pacific (APAC) acute care syndromic testing market is experiencing robust growth and increasing prominence in the region's healthcare landscape. Syndromic testing plays a pivotal role in rapidly diagnosing and managing acute illnesses, offering a timely response to outbreaks and emergencies. This market's expansion is driven by factors such as the rising incidence of infectious diseases, growing awareness of the importance of early diagnosis, and advancements in diagnostic technologies.

In recent years, APAC has witnessed significant investments in healthcare infrastructure and the adoption of innovative diagnostic solutions. These investments have bolstered the acute care syndromic testing market, enabling quicker and more accurate diagnoses in emergency and critical care settings. Furthermore, the ongoing COVID-19 pandemic has underscored the critical role of syndromic testing in public health response, further fueling the demand for such testing solutions across the APAC region.

Market Segmentation:

Segmentation 1: by End User

• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Segmentation 2: by Country

• Japan
• India
• China
• South Korea
• Australia
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments.

Competitive Strategy: The APAC acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the APAC acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

Table of Contents

Executive Summary

1. Markets

• 1.1. Market Scope
  • 1.1.1. Key Questions Answered in the Report
• 1.2. Research Methodology
  • 1.2.1. Acute Care Syndromic Testing Market: Research Methodology
  • 1.2.2. Data Sources
    • 1.2.2.1. Primary Data Sources
    • 1.2.2.2. Secondary Data Sources
  • 1.2.3. Market Estimation Model
  • 1.2.4. Criteria for Company Profiling

2. Market Overview

• 2.1. Overview
• 2.2. Acute Care Syndromic Testing Workflow Analysis
• 2.3. Market Footprint and Growth Potential
• 2.4. Future Potential

3. Industry Insight

• 3.1. Stakeholder's Perspective (N=20)
  • 3.1.1. Physician's Perception
  • 3.1.2. Payor's Perception
  • 3.1.3. Investor's Perception
• 3.2. Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
  • 3.2.1. Regulatory Framework in Asia-Pacific
    • 3.2.1.1. Japan
    • 3.2.1.2. China
    • 3.2.1.3. India
    • 3.2.1.4. South Korea
    • 3.2.1.5. Australia
• 3.3. Product Benchmarking

4. Market Dynamics

• 4.1. Overview
• 4.2. Impact Analysis
• 4.3. Market Drivers
  • 4.3.1. Faster Results Acquired with Syndromic Tests
  • 4.3.2. Increasing Incidence of Infectious Diseases
  • 4.3.3. Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
  • 4.3.4. Reduced Severe Adverse Effects from Pathogens
• 4.4. Market Challenges
  • 4.4.1. Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
  • 4.4.2. Lack of High-Complexity Testing Centres
• 4.5. Market Opportunities
  • 4.5.1. Quick Access to Treatment and Reduced Use of Antibiotics
  • 4.5.2. High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5. Acute Care Syndromic Testing Market (By Region), 2022-2033

• 5.1. Overview
• 5.2. Asia-Pacific
  • 5.2.1. Asia-Pacific Acute Care Syndromic Testing Market, By End User
  • 5.2.2. Asia-Pacific Acute Care Syndromic Testing Market, By Country
    • 5.2.2.1. China
    • 5.2.2.2. Japan
    • 5.2.2.3. India
    • 5.2.2.4. Australia
    • 5.2.2.5. South Korea
    • 5.2.2.6. Rest-of-Asia-Pacific

6. Company Profiles

• 6.1. Overview
• 6.2. Acute Care Syndromic Testing Ecosystem Active Players
• 6.3. Seegene Inc.
  • 6.3.1. Company Overview
  • 6.3.2. Role of Seegene, Inc. in the Acute Care Syndromic Testing Market
  • 6.3.3. Financials
  • 6.3.4. Recent Developments
    • 6.3.4.1. Corporate Strategies
    • 6.3.4.2. Business Strategies
  • 6.3.5. Analyst Perspective
• 6.4. SpeeDx
  • 6.4.1. Company Overview
  • 6.4.2. Role of SpeeDX in the Acute Care Syndromic Testing Market
  • 6.4.3. Analyst Perspective

List of Figures

• Figure 1: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
• Figure 2: History of Known Pandemics
• Figure 3: Share of Acute Care Syndromic Testing Market (by Region), 2022
• Figure 4: Share of Key Developments and Strategies, January 2020-June 2023
• Figure 5: Acute Care Syndromic Testing Market (by Company), Share (%), 2022
• Figure 6: Acute Care Syndromic Testing Market: Research Methodology
• Figure 7: Primary Research Methodology
• Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 9: Top-Down Approach (Segment-Wise Analysis)
• Figure 10: Acute Care Syndromic Testing Workflow
• Figure 11: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
• Figure 12: Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
• Figure 13: Acute Care Syndromic Testing Market Dynamics
• Figure 14: Traditional Testing vs. Syndromic Testing
• Figure 15: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
• Figure 16: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
• Figure 17: Incidence of Common Infectious Diseases in China, 2020
• Figure 18: History of Known Pandemics
• Figure 19: Examples of Cost Reductions
• Figure 20: Time of Diagnosis vs. Disease Effect
• Figure 21: Syndromic Panels Reimbursement Scenario in the U.S.
• Figure 22: Syndromic Panels Reimbursement Scenario in Mexico
• Figure 23: Reduction in Antibiotics Use with Syndromic Testing
• Figure 24: Increasing Synergistic Activities of the Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
• Figure 25: Key Mergers and Acquisitions in the Acute Care Syndromic Testing Market
• Figure 26: Acute Care Syndromic Testing Market Snapshot (by Region)
• Figure 27: Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
• Figure 28: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
• Figure 29: Asia-Pacific Acute Care Syndromic Testing Market (by End User), $Billion, 2022-2033
• Figure 30: Asia-Pacific Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
• Figure 31: Reported Cases of Top 5 Infectious Diseases, China, 2020
• Figure 32: China Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 33: Japan Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 34: India Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 35: Incidence of the Most Common Infectious Diseases in Australia, 2021
• Figure 36: Australia Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 37: South Korea Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 38: Rest-of-Asia-Pacific Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 39: Acute Care Syndromic Testing Market, Total Number of Companies Profiled
• Figure 40: Seegene, Inc.: Product Portfolio
• Figure 41: Seegene, Inc.: Overall Financials, $Million, 2020-2022
• Figure 42: Seegene, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 43: Seegene, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 44: Seegene, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 45: SpeeDX: Product Portfolio

List of Tables

• Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
• Table 2: Acute Care Syndromic Testing Market: Impact Analysis
• Table 3: Key Questions Answered in the Report
• Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
• Table 5: Likert Scale
• Table 6: Impact Analysis of Market Drivers
• Table 7: Impact Analysis of Market Challenges
• Table 8: Popular Assays and Their Turnaround Times
• Table 9: Acute Care Syndromic Testing Ecosystem Active Players